¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tissue growth factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® granulation tissue ÇÑ±Û À°¾ÆÁ¶Á÷
¼³¸í   
  ¸ð¼¼Ç÷°üÀ̠dzºÎÇϸ砿ռºÇϰԠÁõ½ÄÀ» °è¼ÓÇϴ ¾î¸° °áÇÕÁ¶Á÷. Ã¢»ó µî Á¶Á÷ °á¼Õ¿¡ ´ëÇÑ ¼öº¹, À̹°Ã³¸®ÀÇ ±âÁúÈ­, ¿°ÁõÀÌ ¸¸¼ºÀûÀΠ°æ°ú¿¡ Àְųª Á¾¾çÁõ½Ä¿¡ µ¿¹ÝµÈ »çÀ̹°ÁúÀÇ ¹ÝÀÀ¼º ¿°Áõ¿¡¼­ °üÂûµÈ´Ù. ±¸¼º¼ººÐÀº »ý±äÁö ¾ó¸¶ ¾ÈµÇ´Â ¾î¸° À°¾ÆÁ¶Á÷Àº ¼¶À¯¸ð¼¼Æ÷ÀÇ Áõ½Ä, »õ·Î »ý±ä ¸ð¼¼Ç÷°ü°ú ¿©·¯ À¯ÁÖ¼¼Æ÷ ¹× ´Ù¸¥ Áß°£¿±¼¼Æ÷(¹éÇ÷±¸, ¸²ÇÁ±¸, ÇüÁú¼¼Æ÷, Á¶Á÷±¸, ´ÜÇÙ±¸, °Å´ë¼¼Æ÷)µîÀ¸·Î ±¸¼ºµÈ´Ù. À̰ÍÀÌ ½Ã°£ÀÌ Áö³ª ±×¸®µÇ¸é, ¸ð¼¼Ç÷°ü°ú À¯ÁÖ¼¼·Î, ´Ù¸¥Á¶Á÷¼ººÐÀ» °¨¼Ò½ÃÄÑ ¸¸¼ºÈ­ÇÏ¿© ¿À·¡µÈ À°¾Æ°¡ µÇ¸ç °á±¹Àº ¼¶À¯¼¼Æ÷¿Í ¾Æ±³Áú¼¶À¯·Î ±¸¼ºµÈ ¹ÝÈçÁ¶Á÷À¸·Î º¯ÇÑ´Ù.
¿µ¹® tissue ÇÑ±Û Á¶Á÷
¼³¸í   
  Æ¯Á¤ ±¸Á¶¿Í ±â´ÉÀ» °®´Â ¼¼Æ÷ Áý´Ü. ¼¼Æ÷ »çÀÌ¿¡´Â ´Ù¼Ò°£ ¼¼Æ÷°£ÁúÀÌ µé¾î ÀÖ´Ù. ¼¼Æ÷°£Áú¿¡´Â ±Û¸®ÄÚ»ç¹Ì³ë±Û¸®Ä­, È÷µå·Ï½Ã¾ÆÆÄŸÀÌÆ®¿Í °°Àº ±âÁú°ú ¾Æ±³Áú¼¶À¯¿Í °°Àº ¼¶À¯°¡ ¹ß°ßµÈ´Ù. Á¶Á÷¼º»óÀº ±¸¼º¼¼Æ÷¿Í ¼¼Æ÷°£ÁúÀÇ Á¾·ù¿Í ¾ç¿¡ ÀÇÇØ °áÁ¤µÈ´Ù. Á¶Á÷Àº »óÇÇÁ¶Á÷, ÁöÁöÁ¶Á÷, ±ÙÀ°Á¶Á÷, ½Å°æÁ¶Á÷À¸·Î ´ëº°µÇ¸ç, »óÇÇÁ¶Á÷Àº ¼¼Æ÷°£ÁúÀ» °ÅÀÇ °®Áö ¾ÊÀ¸¸ç, ÁöÁöÁ¶Á÷Àº °áÇÕÁ¶Á÷À̳ª »ÀÁ¶Á÷°ú °°ÀÌ ¼¼Æ÷°£ÁúÀ̠dzºÎÇÑ °ÍÀÌ ¸¹´Ù.
¿µ¹® tissue biopsy ÇÑ±Û Á¶Á÷»ý°Ë
¼³¸í   
  È¯ÀÚÀÇ º´ÀûÀΠÁ¶Á÷ÀÇ ÀϺθ¦ ¶¼¾î ³»¼­ º´¸®Á¶Á÷Ç¥º»À» ¸¸µé¾î¼­ Çö¹Ì°æÀûÀ¸·Î °Ë»çÇϴ °Í. ¿Ü°úÀû ¼ö¼úÀç·á·ÎºÎÅÍ º´¸®Á¶Á÷ÇÐÀû °Ë»ç¸¦ ÇÏ¿© »ýü³»ÀÇ º´º¯À» Ãß±¸Çϴ ºÐ¾ß¸¦ ¿Ü°úº´¸®ÇÐÀ̶ó°í ÇÑ´Ù. »ý°Ë¿¡´Â ½û±â»ý°Ë, ÃµÀÚħ»ý°Ë, ²ç¶Õ±â½Ä»ý°Ë, ³»½Ã°æ»ý°Ë ¿Ü¿¡ ¼¼Æ÷ÁøÀ̶ó°í ºÒ¸®¿ì´Â ¹Ú¸®¼¼Æ÷ÁøÀ̳ª ¼¼Ã´¼¼Æ÷Áø µî ¶³¾îÁø ¼¼Æ÷¸¦ µµ¸»°Ë»çÇϴ ¹æ¹ýÀÌ Æ÷ÇԵȴÙ.
¿µ¹® target tissue ÇÑ±Û Ç¥ÀûÁ¶Á÷
¼³¸í   
  È£¸£¸ó¿¡ ´ëÇÏ¿© Ç¥ÀûÀÌ µÇ´Â ¼¼Æ÷¶ó´Â Àǹ̷μ­ ±× È£¸£¸ó¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í Àִ ¼¼Æ÷. ¿¹¸¦ µé¾î Àν¶¸°Àº Àν¶¸° ¼ö¿ëü¸¦ °¡Áø ¼¼Æ÷¸¦ Ç¥Àû¼¼Æ÷·Î ÇÏ¿© ÀÌ ¼¼Æ÷¿¡¸¸ ÀÛ¿ëÇÑ´Ù.
¿µ¹® subcutaneous tissue, subcutis ÇÑ±Û ÇÇÇÏÁ¶Á÷
¼³¸í   
  ÇǺο¡¼­ ÁøÇÇÀÇ ¾Æ·§ºÎºÐÀ» ¸»ÇÔ. ¿©±â¿¡´Â Áö¹æÁ¶Á÷ÀÌ ¸¹´Ù. ±â´ÉÀº ¿­ÀÇ °Ý¸®, Ãæ°ÝÈí¼ö, ¿µ¾çÀúÀå¼Ò µîÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphatic tissue
    ¸²ÇÁÁ¶Á÷
  • microvascular composite tissue transplantation
    ¹Ì¼¼Ç÷°üº¹ÇÕÁ¶Á÷À̽Ä
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´
  • mucosa-associated lymphoid tissue
    Á¡¸·¿¬°ü¸²ÇÁÁ¶Á÷
  • muscular tissue
    ±Ù(À°)Á¶Á÷
  • mesenchymal tissue
    Áß°£¿±Á¶Á÷
  • nervous tissue
    ½Å°æÁ¶Á÷
  • osseous tissue
    »ÀÁ¶Á÷, °ñÁ¶Á÷
  • osteogenic tissue
    »ÀÇü¼ºÁ¶Á÷, °ñÇü¼ºÁ¶Á÷
  • osteoid tissue
    Dz»ÀÁ¶Á÷, À¯°ñÁ¶Á÷
  • reticular tissue
    ±×¹°Á¶Á÷, ¸Á»óÁ¶Á÷
  • soft tissue
    ¹°··Á¶Á÷, ¿¬Á¶Á÷
  • soft tissue coverage
    ¿¬Á¶Á÷µ¤±â
  • scar tissue
    ÈäÅÍÁ¶Á÷
  • subcutaneous tissue
    ÇǺιØÁ¶Á÷, ÇÇÇÏÁ¶Á÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • elastic tissue
    ź·ÂÁ¶Á÷
  • erectile tissue
    ¹ß±âÁ¶Á÷
  • granulation tissue
    À°¾ÆÁ¶Á÷
  • interstitial tissue
    »çÀÌÁúÁ¶Á÷, °£ÁúÁ¶Á÷
  • lymphatic tissue
    ¸²ÇÁÁ¶Á÷
  • mesenchymal tissue
    Áß°£¿±Á¶Á÷
  • muscular tissue
    ±ÙÀ°Á¶Á÷
  • nervous tissue
    ½Å°æÁ¶Á÷
  • osseous tissue
    »ÀÁ¶Á÷
  • osteoid tissue
    »À¸ð¾çÁ¶Á÷, Dz»ÀÁ¶Á÷
  • retained placental tissue
    ÀÜ·ùŹÝÁ¶Á÷
  • reticular tissue
    ±×¹°Á¶Á÷, ¼¼¸ÁÁ¶Á÷
  • scar tissue
    ÈäÅÍÁ¶Á÷
  • soft tissue
    ¿¬Á¶Á÷, ¹°··Á¶Á÷
  • subcutaneous tissue
    ÇǺιØÁ¶Á÷, ÇÇÇÏÁ¶Á÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´, ½Â¸ðÆÇ¸·º´
  • tissue damage
    Á¶Á÷¼Õ»ó
  • tissue degeneration
    Á¶Á÷º¯¼º
  • tissue dose
    Á¶Á÷¼±·®
  • elastic tissue
    ź·ÂÁ¶Á÷
  • epithelial tissue
    »óÇÇÁ¶Á÷
  • erectile tissue
    ¹ß±âÁ¶Á÷
  • tissue expander
    Á¶Á÷È®Àå±â
  • tissue expansion
    Á¶Á÷È®Àå(¼ú)
  • tissue factor
    Á¶Á÷ÀÎÀÚ
  • granulation tissue
    À°¾ÆÁ¶Á÷
  • gut-associated lymphatic tissue
    âÀÚ¿¬°ü¸²ÇÁÁ¶Á÷
  • hemopoietic tissue
    Ç÷±¸Çü¼ºÁ¶Á÷, Á¶Ç÷Á¶Á÷
  • tissue hypoxia
    Á¶Á÷Àú»ê¼ÒÁõ
  • interstitial tissue
    »çÀÌÁúÁ¶Á÷, °£ÁúÁ¶Á÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gut-associated lymphatic tissue (GALT)
    Àå-¿¬°ü ¸²ÇÁÁ¶Á÷
  • hemopoietic tissue
    Ç÷__ü¼ºÁ¶Á__ Á¶Ç÷Á¶Á÷.
  • hemopoietic tissue
    Ç÷±¸Çü¼ºÁ¶Á÷
  • hemopoietic tissue
    Ç÷±¸Çü¼ºÁ¶Á÷, Á¶Ç÷Á¶Á÷.
  • hemopoietic tissue
    Ç÷¾×Çü¼ºÁ¶Á÷
  • immunity, tissue
    Á¶Á÷¸é¿ª
  • pigment connective tissue
    »ö¼Ò°áÇÕÁ¶Á÷
  • pigment tissue
    »ö¼ÒÁ¶Á÷(ßäáÈðÚòÄ).
  • placental tissue
    ŹÝÁ¶Á÷.
  • prechondral tissue
    Dz¿¬°ñÁ¶Á÷
  • primitive connective tissue
    ¿ø½Ã°áÇÕÁ¶Á÷(¡­Ì¿ùêðÚòÄ) °£¿±(Êàç¨) .
  • regular connective tissue
    ±ÔÄ¢¼º °áÇÕÁ¶Á÷, Á¤Çü°áÇÕÁ¶Á÷(ïáû¡Ì¿ùêðÚòÄ).
  • renewal tissue
    Àç»ýÁ¶Á÷
  • B cell growth factor
    B ¼¼Æ÷¼ºÀåÀÎÀÚ
  • B cell growth factor (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • apical growth
    Á¤´Ü¼ºÀå, ÷´Ü¼ºÀå, ³¡¼ºÀå
  • appositional growth
    µ¡ºÙÀ̼ºÀå
  • asynchronous growth
    ºñµ¿Á¶¼º, ºñµ¿½Ã¼º, ºñµ¿±â¼ºÁõ½Ä
  • bacterial growth
    ¼¼±Õ»ýÀå<¼ºÀå>(¡­ßæíþ <à÷íþ>).
  • bacterial growth
    ¼¼±Õ»ýÀå<¼ºÀå>(¡­ßæíþ <à÷íþ>).
  • bacterial growth curve
    ¼¼±ÕÁõ½Ä°î¼±
  • bacterial growth rate
    ¼¼±ÕÁõ½ÄÀ²
  • bone growth
    °ñ ¼ºÀå(Íéà÷íþ).
  • cell growth
    ¼¼Æ÷¼ºÀå (¡­à÷íþ)
  • cell growth pattern
    ¼¼Æ÷¼ºÀå¸ð¾ç<--¾ç½Ä>
  • cell growth,ligand receptor binding
    ¸®°£µå¼ö¿ë±â°áÇÕ (¡­áôé»ÐïÌ¿ùê)
  • curve, growth
    Áõ½Ä°î¼±
  • curve, single-step growth
    ÀÏȸÁõ½Ä°î¼±
  • cycle, growth
    Áõ½ÄÁÖ±â
  • developmental disease =growth abnor mal ity
    ¹ß´ÞÀÌ»ó(¡­ì¶ßÈ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Reticular tissue
    ¼¼¸ÁÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼¸ÁÁ¶Á÷
  • Cellular connective tissue
    ¼¼Æ÷¼º°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼Æ÷¼º°áÇÕÁ¶Á÷
  • Neural crest tissue
    ½Å°æ´É¼±Á¶Á÷
    [¿¾ ¿ë¾î] ½Å°æ¸ªÁ¶Á÷
  • Tissue of neural crest (Mesectoderm)
    ½Å°æ´É¼±Á¶Á÷ (Áß°£¿Ü¹è¿±)
    [¿¾ ¿ë¾î] ½Å°æ¸ªÁ¶Á÷
  • Nervous tissue (Neuroblastoma)
    ½Å°æÁ¶Á÷ (½Å°æ¸ð¼¼Æ÷Á¾)
    [¿¾ ¿ë¾î] ½Å°æÁ¶Á÷
  • Cardiac muscular tissue
    ½ÉÀå±ÙÀ°Á¶Á÷
    [¿¾ ¿ë¾î] ½É±ÙÁ¶Á÷
  • Conducting tissue of heart
    ½ÉÀåÀüµµÁ¶Á÷
    [¿¾ ¿ë¾î] ½ÉÀåÀüµµ°è
  • Collagenous connective tissue
    ¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ±³¿ø°áÇÕÁ¶Á÷
  • Cartilage tissue
    ¿¬°ñÁ¶Á÷ [¹°··»ÀÁ¶Á÷]
    [¿¾ ¿ë¾î] ¿¬°ñÁ¶Á÷
  • Submucosal tissue
    Á¡¸·¹ØÁ¶Á÷
    [¿¾ ¿ë¾î] Á¡¸·ÇÏÁ¶Á÷
  • Abnormality of tissue
    Á¶Á÷ÀÌ»ó
    [¿¾ ¿ë¾î] Á¶Á÷ÀÌ»ó
  • Notochordal tissue (Chordoma)
    ô»èÁ¶Á÷ (ô»èÁ¾)
    [¿¾ ¿ë¾î] ô»èÁ¶Á÷
  • Lamellar bone tissue
    ÃþÆÇ»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] ÃþÆÇ¼º°ñÁ¶Á÷
  • Compact bone tissue
    Ä¡¹Ð»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] Ä¡¹Ð°ñÁ¶Á÷
  • Dense collagenous connective tissue
    Ä¡¹Ð¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] Ä¡¹Ð°áÇÕÁ¶Á÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tissue-specific enzyme
    Á¶Á÷ ƯÀÌ È¿¼Ò (ðÚòÄ÷åì¶ý£áÈ)
  • tissue thromboplastin
    Á¶Á÷(ðÚòÄ)Æ®·Òº¸ÇÃ¶ó½ºÆ¾
  • white adipose tissue
    ÈØ Áö¹æÁ¶Á÷ (ò·Û¸ðÚòÄ)
  • anchorage independent growth
    °íÁ¤ºñÀÇÁ¸¼º¼ºÀå(ͳïÒÞªëîðíàõà÷íþ)
  • asynchronous growth
    ºñµ¿½Ã¼º ¼ºÀå (ÞªÔÒãÁàõà÷íþ)
  • balanced growth
    ±ÕÇü¼ºÀå(гû¬à÷íþ)
  • chain-growth polymer
    »ç½½½ÅÀå(ãßíþ)ÁßÇÕü(ñìùêô÷)
  • comb growth test
    °è°ü ¼ºÀå½ÃÇè(ͮήà÷íþãËúÐ)
  • confluent growth
    Àü¸é¼ºÀå(îïØüà÷íþ)
  • density-dependent growth
    "¹ÐµµÀÇÁ¸ ¼ºÀå(ÚËÓøëîðíà÷íþ), (ÔÒ) contact inhibition"
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ (øúù«à÷íþì×í­)
  • epithelial growth factor
    »óÇǼºÀåÀÎÀÚ (ß¾ù«à÷íþì×í­)
  • exponential growth
    Áö¼ö ¼ºÀå (ò¦â¦à÷íþ)
  • exponential growth rate constant
    Áö¼ö ¼ºÀå¼Óµµ »ó¼ö (ò¦â¦à÷íþáÜÓøßÈâ¦)
  • growth curve
    ¼ºÀå°î¼± (à÷íþÍØàÊ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • granulation tissue
    À°¾ÆÁ¶Á÷
  • inflammatory tissue
    ¿°ÁõÁ¶Á÷
  • interstitial tissue
    °£ÁúÁ¶Á÷
  • lattice in stationary tissue
    Á¤ÀûÁ¶Á÷³»°ÝÀÚ
  • MALT(mucosa associated lymphoid tissue)
    Á¡¸·°ü·Ã¸²ÇÁÁ¶Á÷
  • mesenchymal tissue
    Áß°£¿±Á¶Á÷, °£¿±Á¶Á÷
  • muscle tissue
    ±ÙÀ°Á¶Á÷, ±ÙÁ¶Á÷
  • osseous tissue
    »ÀÁ¶Á÷, °ñÁ¶Á÷
  • osteoblastic tissue
    °ñÇü¼ºÁ¶Á÷
  • proper connective tissue
    °íÀ¯°áÇÕÁ¶Á÷
  • pseudogating in flowing tissue
    À¯µ¿Á¶Á÷¿¡¼­ À§°ÔÀÌÆÃ
  • reticular connective tissue
    ¼¼¸Á°áÇÕÁ¶Á÷
  • reticular tissue
    ¼¼¸ÁÁ¶Á÷
  • retropharyngeal soft tissue space
    ÀεÎÈĺο¬ºÎÁ¶Á÷
  • scar tissue
    ¹ÝÈçÁ¶Á÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TCID50 median tissue culture infective dose; 50% tissue culture infective dose
ANF Atrial Natriuretic Factors
ECF   1) Eosinophilic Chemotatic Factors
  2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾×
NCF Neutrophilic Chemotatic Factors
CDSRF chronic disease and sociodemographic risk factors
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IGFBPs Insulin-like growth factors and their binding proteins
IGF-II Insulin-like growth factors I and II
CTGF Connective Tissue Growth Factor
AEF Allogeneic effect factors
APF Anti-perinuclear factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • exponential phase of growth
    ´ë¼ö Áõ½Ä±â, °¡¼Ó ¼ºÀå±â
  • horizontal growth
    ¼öÆò ¼ºÀå
  • human growth hormone
    ¼ºÀå È£¸£¸ó
    ¼ºÀåÀ» ÃËÁøÇÏ´Â ¹°ÁúÀ» ÃÑĪÇϸç, ƯÈ÷ ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÀ» ¸»ÇÑ´Ù.
  • neural growth
    ½Å°æ°èÇü ¼ºÀå
  • no growth
    ¹«¼ºÀå
  • nonbleeding growth
    ºñÃâÇ÷¼º ¼ºÀå
  • one step growth
    ÀÏ´Ü Áõ½Ä
  • papillomatous growth
    À¯µÎ¼º ¼ºÀå
    À¯µÎÁ¾°ú °°ÀÌ ´Ù¹ßÀûÀ¸·Î ÀϾ´Â ¼ºÀå.
  • polypoid growth
    Æú¸³ Áõ½Ä
  • prenatal facial growth
    Ãâ»ýÀüÀÇ ¾ó±¼ ¼ºÀå
  • proliferative growth
    Áõ½Ä¼º ¼ºÀå
  • retardation of growth
    ¼ºÀå Áö¿¬
  • somatic growth
    ½ÅüÇü ¼ºÀå, ü¼º ¼ºÀå
  • stationary phase of growth
    Áõ½Ä Á¤Áö±â
  • too much growth
    Áõ½Ä
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
glaucoma, risk factors If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites).
(12 Dec 1998)
releasing factors Hormones produced by the hypothalamus whichstimulate the release of other hormones in the pituitary gland.
(09 Oct 1997)
resistance factors Plasmid's carrying genes responsible for antibiotic (or antibacterial drug) resistance among bacteria (notably Enterobacteriaceae); they may be conjugative or nonconjugative plasmid's, the former possessing transfer genes (resistance transfer factor) lacking in the latter.
Synonym: R factors, R plasmids, resistance factors, resistance-transferring episomes.
(05 Mar 2000)
peptide elongation factors Protein factors uniquely required during the elongation phase of protein synthesis.
(12 Dec 1998)
peptide initiation factors Protein factors uniquely required during the initiation phase of protein synthesis.
(12 Dec 1998)
peptide termination factors Proteins that are exclusively involved in the termination reactions of protein synthesis on the ribosome.
(12 Dec 1998)
C factors Proteins that restore phosphorylating ability to mitochondria that have lost it, i.e., have become "uncoupled" so that oxidation and electron transport no longer produces ATP. Usually termed coupling factor F1, F2, etc.
Synonym: C factors.
(05 Mar 2000)
r factors A class of plasmids that transfer antibiotic resistance from one bacterium to another by conjugation.
(12 Dec 1998)
rheumatoid factors Antibodies in the serum of individuals with rheumatoid arthritis that react with antigenic determinants or immunoglobulins that enhance agglutination of suspended particles coated with pooled human gamma-globulin. Rheumatoid factors also occur in other autoimmune and certain infectious diseases.
(05 Mar 2000)
chemotactic factors Chemical substances that attract or repel cells or organisms. The concept denotes especially those factors released as a result of tissue injury, invasion, or immunologic activity, that attract leukocytes, macrophages, or other cells to the site of infection or insult.
(12 Dec 1998)
chemotactic factors, eosinophil Cytotaxins liberated from normal or invading cells that specifically attract eosinophils; they may be complement fragments, lymphokines, neutrophil products, histamine or other; the best known is the tetrapeptide ecf-a, released mainly by mast cells.
(12 Dec 1998)
chemotactic factors, macrophage Cytotaxins liberated from normal or invading cells that specifically attract macrophages. They may be lymphokines, products of antigen, antibody and complement interactions or other.
(12 Dec 1998)
risk factors An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
(12 Dec 1998)
meteorological factors The atmospheric phenomena which pertain to climate and weather.
(12 Dec 1998)
clearing factors Lipoprotein lipases that appear in plasma during lipaemia and catalyze hydrolysis of triglycerides only when the latter are bound to protein and when an acceptor (e.g., serum albumin) is present, thus "clearing" the plasma.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • negative growth
    (°æÁ¦ÀÇ)¸¶À̳ʽº ¼ºÀå
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • positive growth
    Ç÷¯½º ¼ºÀå
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á